Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

Analysis of Profitability Ratios

Microsoft Excel

Profitability Ratios (Summary)

AbbVie Inc., profitability ratios

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Return on Sales
Gross profit margin 62.42% 70.00% 68.96% 66.41% 77.64%
Operating profit margin 23.49% 31.21% 31.89% 24.81% 39.03%
Net profit margin 8.95% 20.39% 20.54% 10.08% 23.69%
Return on Investment
Return on equity (ROE) 46.94% 68.60% 74.91% 35.30%
Return on assets (ROA) 3.61% 8.53% 7.88% 3.07% 8.84%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. AbbVie Inc. gross profit margin ratio improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. AbbVie Inc. operating profit margin ratio deteriorated from 2021 to 2022 and from 2022 to 2023.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. AbbVie Inc. net profit margin ratio deteriorated from 2021 to 2022 and from 2022 to 2023.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. AbbVie Inc. ROE deteriorated from 2021 to 2022 and from 2022 to 2023.
ROA A profitability ratio calculated as net income divided by total assets. AbbVie Inc. ROA improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023.

Gross Profit Margin

AbbVie Inc., gross profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Gross margin 33,903 40,640 38,751 30,417 25,827
Net revenues 54,318 58,054 56,197 45,804 33,266
Profitability Ratio
Gross profit margin1 62.42% 70.00% 68.96% 66.41% 77.64%
Benchmarks
Gross Profit Margin, Competitors2
Amgen Inc. 68.60% 74.17% 73.44% 74.59% 80.38%
Bristol-Myers Squibb Co. 76.24% 78.04% 78.57% 72.31% 69.10%
Eli Lilly & Co. 79.25% 76.77% 74.18% 77.66% 78.85%
Gilead Sciences Inc. 75.87% 79.03% 75.56% 81.23% 78.86%
Johnson & Johnson 68.82% 67.26% 68.16% 65.58% 66.42%
Merck & Co. Inc. 73.17% 70.63% 72.02% 67.74% 69.87%
Pfizer Inc. 57.34% 65.77% 62.08% 79.26% 80.25%
Regeneron Pharmaceuticals Inc. 86.16% 87.18% 84.83% 86.82% 90.05%
Thermo Fisher Scientific Inc. 39.90% 42.24% 50.08% 49.67% 44.35%
Vertex Pharmaceuticals Inc. 87.21% 87.90% 88.06% 88.14% 86.84%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Gross profit margin = 100 × Gross margin ÷ Net revenues
= 100 × 33,903 ÷ 54,318 = 62.42%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. AbbVie Inc. gross profit margin ratio improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023.

Operating Profit Margin

AbbVie Inc., operating profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Operating earnings 12,757 18,117 17,924 11,363 12,983
Net revenues 54,318 58,054 56,197 45,804 33,266
Profitability Ratio
Operating profit margin1 23.49% 31.21% 31.89% 24.81% 39.03%
Benchmarks
Operating Profit Margin, Competitors2
Amgen Inc. 29.35% 38.57% 31.44% 37.70% 43.57%
Bristol-Myers Squibb Co. 16.18% 17.96% 15.91% -21.60% 22.62%
Eli Lilly & Co. 18.92% 24.97% 22.45% 24.69% 22.29%
Gilead Sciences Inc. 28.24% 27.17% 36.72% 16.72% 19.38%
Johnson & Johnson 24.90% 24.63% 24.95% 23.60% 24.15%
Merck & Co. Inc. 3.92% 30.27% 25.74% 16.47% 24.77%
Pfizer Inc. 0.38% 34.83% 23.91% 19.47% 25.46%
Regeneron Pharmaceuticals Inc. 30.85% 38.93% 55.67% 42.09% 28.10%
Thermo Fisher Scientific Inc. 16.00% 18.69% 25.57% 24.19% 17.99%
Vertex Pharmaceuticals Inc. 38.83% 48.23% 36.73% 46.03% 28.77%
Operating Profit Margin, Sector
Pharmaceuticals, Biotechnology & Life Sciences 17.62% 28.54% 26.95% 18.70% 26.27%
Operating Profit Margin, Industry
Health Care 9.45% 13.29% 13.19% 10.52% 12.41%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Operating profit margin = 100 × Operating earnings ÷ Net revenues
= 100 × 12,757 ÷ 54,318 = 23.49%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. AbbVie Inc. operating profit margin ratio deteriorated from 2021 to 2022 and from 2022 to 2023.

Net Profit Margin

AbbVie Inc., net profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Net earnings attributable to AbbVie Inc. 4,863 11,836 11,542 4,616 7,882
Net revenues 54,318 58,054 56,197 45,804 33,266
Profitability Ratio
Net profit margin1 8.95% 20.39% 20.54% 10.08% 23.69%
Benchmarks
Net Profit Margin, Competitors2
Amgen Inc. 24.96% 26.42% 24.25% 29.97% 35.32%
Bristol-Myers Squibb Co. 17.83% 13.71% 15.08% -21.20% 13.15%
Eli Lilly & Co. 15.36% 21.88% 19.71% 25.24% 37.27%
Gilead Sciences Inc. 21.03% 17.02% 23.05% 0.51% 24.35%
Johnson & Johnson 41.28% 18.90% 22.26% 17.82% 18.42%
Merck & Co. Inc. 0.61% 24.49% 26.79% 14.72% 21.01%
Pfizer Inc. 3.62% 31.27% 27.04% 22.95% 31.45%
Regeneron Pharmaceuticals Inc. 30.14% 35.64% 50.25% 41.35% 26.91%
Thermo Fisher Scientific Inc. 13.99% 15.47% 19.70% 19.79% 14.47%
Vertex Pharmaceuticals Inc. 36.68% 37.20% 30.92% 43.70% 28.27%
Net Profit Margin, Sector
Pharmaceuticals, Biotechnology & Life Sciences 17.88% 22.57% 23.52% 13.96% 23.55%
Net Profit Margin, Industry
Health Care 8.11% 10.32% 10.91% 7.86% 10.19%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Net profit margin = 100 × Net earnings attributable to AbbVie Inc. ÷ Net revenues
= 100 × 4,863 ÷ 54,318 = 8.95%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. AbbVie Inc. net profit margin ratio deteriorated from 2021 to 2022 and from 2022 to 2023.

Return on Equity (ROE)

AbbVie Inc., ROE calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Net earnings attributable to AbbVie Inc. 4,863 11,836 11,542 4,616 7,882
Stockholders’ equity (deficit) 10,360 17,254 15,408 13,076 (8,172)
Profitability Ratio
ROE1 46.94% 68.60% 74.91% 35.30%
Benchmarks
ROE, Competitors2
Amgen Inc. 107.78% 178.97% 87.96% 77.20% 81.07%
Bristol-Myers Squibb Co. 27.27% 20.37% 19.46% -23.84% 6.66%
Eli Lilly & Co. 48.65% 58.64% 62.16% 109.79% 319.09%
Gilead Sciences Inc. 24.81% 21.62% 29.55% 0.68% 23.91%
Johnson & Johnson 51.11% 23.36% 28.20% 23.25% 25.42%
Merck & Co. Inc. 0.97% 31.57% 34.17% 27.91% 37.99%
Pfizer Inc. 2.38% 32.79% 28.47% 15.21% 25.77%
Regeneron Pharmaceuticals Inc. 15.22% 19.14% 43.03% 31.86% 19.08%
Thermo Fisher Scientific Inc. 12.83% 15.80% 18.94% 18.47% 12.45%
Vertex Pharmaceuticals Inc. 20.59% 23.88% 23.19% 31.22% 19.34%
ROE, Sector
Pharmaceuticals, Biotechnology & Life Sciences 22.37% 29.77% 31.77% 18.32% 29.64%
ROE, Industry
Health Care 18.01% 22.38% 22.87% 16.20% 21.01%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
ROE = 100 × Net earnings attributable to AbbVie Inc. ÷ Stockholders’ equity (deficit)
= 100 × 4,863 ÷ 10,360 = 46.94%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. AbbVie Inc. ROE deteriorated from 2021 to 2022 and from 2022 to 2023.

Return on Assets (ROA)

AbbVie Inc., ROA calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Net earnings attributable to AbbVie Inc. 4,863 11,836 11,542 4,616 7,882
Total assets 134,711 138,805 146,529 150,565 89,115
Profitability Ratio
ROA1 3.61% 8.53% 7.88% 3.07% 8.84%
Benchmarks
ROA, Competitors2
Amgen Inc. 6.91% 10.06% 9.63% 11.54% 13.13%
Bristol-Myers Squibb Co. 8.43% 6.53% 6.40% -7.61% 2.65%
Eli Lilly & Co. 8.19% 12.62% 11.44% 13.28% 21.17%
Gilead Sciences Inc. 9.12% 7.27% 9.16% 0.18% 8.74%
Johnson & Johnson 20.98% 9.57% 11.47% 8.41% 9.59%
Merck & Co. Inc. 0.34% 13.30% 12.35% 7.72% 11.66%
Pfizer Inc. 0.94% 15.91% 12.11% 6.23% 9.72%
Regeneron Pharmaceuticals Inc. 11.95% 14.85% 31.75% 20.47% 14.29%
Thermo Fisher Scientific Inc. 6.07% 7.15% 8.12% 9.23% 6.33%
Vertex Pharmaceuticals Inc. 15.92% 18.30% 17.44% 23.07% 14.15%
ROA, Sector
Pharmaceuticals, Biotechnology & Life Sciences 7.37% 10.84% 10.64% 5.51% 9.31%
ROA, Industry
Health Care 6.45% 8.39% 8.25% 5.52% 7.21%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
ROA = 100 × Net earnings attributable to AbbVie Inc. ÷ Total assets
= 100 × 4,863 ÷ 134,711 = 3.61%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. AbbVie Inc. ROA improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023.